Radiosynthesis of 11C-levetiracetam: A potential marker for PET imaging of SV2A expression

ACS Medicinal Chemistry Letters

Volumn 5, Issue 10, 2014, Pages 1152-1155

  Cai, Hancheng ^a,b,c,d   Mangner, Thomas J ^a,b   Muzik, Otto ^a,b   Wang, Ming Wei ^e   Chugani, Diane C ^a,b   Chugani, Harry T ^a,b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

carbon 11; Levetiracetam; positron emission tomography; synaptic vesicle protein 2A

Indexed keywords

4- HLOROBUTYRYL CHLORIDE; ALKANE DERIVATIVE; AMINONITRILE C 11; AMMONIA; ETIRACETAM; ETIRACETAM C 11; NITRILE; PROPAN 1 IMINE; PROPIONALDEHYDE; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; POSITRON EMISSION TOMOGRAPHY; RADIOSYNTHESIS;

EID: 84907937309     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500285t     Document Type: Article

References (26)

1. Lyseng-Williamson, K. A. Levetiracetam: a review of its use in epilepsy Drugs 2011, 71, 489-514
2. Sanchez, P. E.; Zhu, L.; Verret, L.; Vossel, K. A.; Orr, A. G.; Cirrito, J. R.; Devidze, N.; Ho, K.; Yu, G. Q.; Palop, J. J.; Mucke, L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model Proc. Natl. Acad. Sci. U.S.A. 2012, 109, E2895-2903
3. Martinez-Granero, M. A.; Garcia-Perez, A.; Montanes, F. Levetiracetam as an alternative therapy for Tourette syndrome Neuropsychiatr. Dis. Treat. 2010, 6, 309-316
4. Rajapakse, T.; Pringsheim, T. Pharmacotherapeutics of Tourette syndrome and stereotypies in autism Semin. Pediatr. Neurol. 2010, 17, 254-260
5. Farooq, M. U.; Bhatt, A.; Majid, A.; Gupta, R.; Khasnis, A.; Kassab, M. Y. Levetiracetam for manag-ing neurologic and psychiatric disorders Am. J. Health Syst. Pharm. 2009, 66, 541-561
6. Saricicek, S.; Maloney, A.; Muralidharan, K.; Ruf, A.; Blumberg, B.; Sanacora, H. P.; Lorberg, G.; Pittman, B.; Bhagwagar, B.; Levetiracetam, Z. in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial J. Clin Psychiatry 2011, 72, 744-750
7. The data come from www.clinicaltrials.gov.
8. Lynch, B. A.; Lambeng, N.; Nocka, K.; Kensel-Hammes, P.; Bajjalieh, S. M.; Matagne, A.; Fuks, B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 9861-9866
9. Surges, R.; Volynski, K. E.; Walker, M. C. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited Ther. Adv. Neurol. Disord. 2008, 1, 13-24
10. Mendoza-Torreblanca, J. G.; Vanoye-Carlo, A.; Phillips-Farfan, B. V.; Carmona-Aparicio, L.; Gomez-Lira, G. Synaptic vesicle protein 2A: basic facts and role in synaptic function Eur. J. Neurosci. 2013, 38, 3529-39
11. Hildenbrand, S.; Baqi, Y.; Müller, C. E. Synthesis of tritium-labeled levetiracetam ((2 S)-2-(2-oxopyrrolidin-1-yl)butanamide) with high specific activity J. Labelled Compd. Radiopharm 2011, 55, 48-51
12. Wong, D. F.; Tauscher, J.; Grunder, G. The role of imaging in proof of concept for CNS drug discovery and development Neuropsychopharmacology 2009, 34, 187-203
13. 18F]UCB-H EJNMMI Res. 2013, 3, 35-42
14. Mercier, J.; Archen, L.; Bollu, V.; Carre, S.; Evrard, Y.; Jnoff, E.; Kenda, B.; Lallemand, B.; Michel, P.; Montel, F.; Moureau, F.; Price, N.; Quesnel, Y.; Sauvage, X.; Valade, A.; Provins, L. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands ChemMedChem 2014, 9, 693-698
15. 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain J. Nucl. Med. 2014, 55, 1-6
16. Josephson, L.; Rudin, M. Barriers to clinical translation with diagnostic drugs J. Nucl. Med. 2013, 54, 329-332
17. Rotstein, B. H.; Liang, S. H.; Holland, J. P.; Collier, T. L.; Hooker, J. M.; Wilson, A. A.; Vasdev, N. 11CO2 fixation: a renaissance in PET radiochemistry Chem. Commun. 2013, 49, 5621-5629
18. Boschia, F.; Campsa, P.; Comes-Franchinib, M.; Muñoz-Torreroa, D.; Riccib, A.; Sanchez, L. A synthesis of levetiracetam based on (S)- N -phenylpantolactam as a chiral auxiliary Tetrahedron: Asymmetry 2005, 16, 3739-3745
19. Neugnot, B.; Cintrat, J.-C.; Rousseau, B. A new highly chemoselective isomerization of allylamides Tetrahedron 2004, 60, 3575-3579
20. Su, C.; Williard, P. G. Isomerization of allyl ethers initiated by lithium diisopropylamide Org. Lett. 2010, 12, 5378-5381
21. Fahey, R. C.; McPherson, C. A.; Smith, R. A. Reaction of alkenes with hydrogen bromide in acetic acid. Polar addition via the Ad3 mechanism J. Am. Chem. Soc. 1974, 96, 4534-4542
22. Knapp, F. F., Jr. Steroid synthesis. The modified Hunsdiecker degradation of bile acids and related compounds Steroids 1979, 33, 245-249
23. Kaupp, G.; Matthies, D. Organic gas-solid reactions with stilbenes, chalcones, and enamides Chem. Ber. 1987, 120, 1897-1903
24. Barton, D. H. R.; Crich, D.; Motherwell, W. B. The invention of new radical chain reactions. Part VIII. Radical chemistry of thiohydroxamic esters; A new method for the generation of carbon radicals from carboxylic acids Tetrahedron 1985, 41, 3901-3924
25. 11C]-labeled d-and l -enantiomers of lactic acid Appl. Radiat. Isot. 2006, 64, 1613-1622
26. 11C)tyrosine in human brain using positron emission tomography Eur. J. Nucl. Med. 1987, 13, 288-291